 EMERYVILLE, Calif., Sept. 30, 2021 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an on-going 12-month Phase 3 open-label extension OLE study Study 1601; Part 2 showing that treatment with FINTEPLA fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures in patients with Lennox-Gastaut syndrome LGS on antiseizure medications ASMs. LGS is a rare, severe childhood-onset form of epilepsy in which seizures are extremely difficult to control and are associated with significant cognitive, behavioral, and motor disabilities. These data were presented today at the Child Neurology Society CNS 2021 Annual Meeting, which is being held September 29 - October 2, 2021. 